**Review Article**

**Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy**

**Xiao-Jing Yang**, **Ya-Ming Xi**, and **Zi-Jian Li**

*Division of Hematology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China*

Correspondence should be addressed to Ya-Ming Xi; xiyaming02@163.com and Zi-Jian Li; lizijian@live.com

Received 21 November 2018; Revised 5 March 2019; Accepted 13 March 2019; Published 28 March 2019

Academic Editor: Carlo Visco

Copyright © 2019 Xiao-Jing Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hematological malignancies including leukemia and lymphoma can severely impact human health. With the current therapies combined with chemotherapy, stem cell transplantation, radiotherapy, and immunotherapy, the prognosis of hematologic malignancies improved significantly. However, most hematological malignancies are still incurable. Therefore, research for novel treatment options was continuing with the natural product as one source. Icaritin is a compound extracted from a traditional Chinese herb, *Epimedium Genus*, and demonstrated an antitumor effect in various neoplasms including hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In hematological malignancies, icaritin showed multiple cytotoxic effects to induce apoptosis, arrest the cell cycle, inhibit proliferation, promote differentiation, restrict metastasis and infiltration, and suppress the oncogenic virus. The proved underlying mechanisms of the cytotoxic effects of icaritin are different in various cell types of hematological malignancies but associated with the critical cell signal pathway, including PI3K/Akt, JAK/STAT3, and MAPK/ERK/JNK. Although the primary target of icaritin is still unspecified, the existing evidence indicates that icaritin is a potential novel therapeutic agent for neoplasms as with hematological malignancies. Here, in the field of hematology, we reviewed the reported activity of icaritin in hematologic malignancies and the underlying mechanisms and recognized icaritin as a candidate for therapy of hematological malignancies.

### 1. Introduction

Hematological malignancies are known as a series of malignant diseases affecting the blood, bone marrow, lymph, and lymphatic system, which finally lead to dys hematopoiesis. So far, primary treatment includes chemotherapy, radiotherapy, immunotherapy, and autologous or allogeneic stem cell transplantation. Various sorts of anticancer drugs with different mechanisms and targets are developed to attack the cancer cell colony and block disease progression. Outstanding achievements have been made, accompanied by limitations. Conventional drugs bring adverse reactions and sometimes lead to resistance that cannot be ignored [1]. Consequently, new compounds from plants and herbs attract much attention in the hope of devising novel drugs for cancer therapy and prevention [2].

Icaritin, a hydrolytic product of icariin, is extracted from the traditional Chinese herb *Epimedium Genus*. Previous studies demonstrated that icaritin possesses various pharmacological and biological activities in nonneoplastic diseases, including protection of neuron against amyloid-induced neurotoxicity [3], promotion of differentiation from embryonic stem cell into cardiomyocyte [4], enhancement of osteoblastic and suppression of osteoclastic differentiation and activity [5–11], immunomodulation [12, 13], enhancement of self-renewal of mouse embryonic stem cells (mESCs) [14], recovery of UVB-induced photoaging of human keratinocytes [15], and improvement of hematopoietic function in cyclophosphamide-induced myelosuppression mice [16].

Recently, icaritin has attracted great attention in terms of its inhibition of various solid tumors including breast cancer [17–23], hepatocellular carcinoma [24–26], lung cancer [27], oral squamous cell carcinoma [28, 29], endometrial cancer [30, 31], esophageal cancer [32], colorectal cancer [33, 34], glioblastoma [17, 35, 36], ovarian cancer [37], and osteosarcoma [38]. Apart from the common cytotoxic effects, icaritin exhibits some other distinctive properties of restraining tumor progression. For example, icaritin induces cell differentiation, suppresses tumor cell migration, and inhibits cancer stem/progenitor cell growth [18, 32, 39, 40].
Except for investigations of icaritin on the solid tumor, a series of studies on hematological cancer were conducted and proved the significant inhibitory effect of icaritin on various hematological cancer cells, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma (MM), and lymphoma [40–44]. Moreover, pivotal signaling pathways were found to be responsible for the proliferative suppression induced by icaritin in hematological cancer also. Though how icaritin suppresses cancer cells through the intricate signal network remains equivocal, these studies indicated that icaritin might be a potential candidate for hematological malignancies. Such review encompasses the proven antitumor effect and mechanism of icaritin as a promising novel agent for hematological malignancies.

2. Effects and Mechanisms of Icaritin on Hematological Malignancies

2.1. Icaritin Induced Apoptosis of Hematological Malignancy Cells

Apoptosis describes a kind of cell death activated by intracellular suicide program. Over the past decades, triggering apoptosis in tumor cells is seemingly regarded as an effective strategy for cancer therapy [20]. Apoptosis occurs through both the extrinsic and the intrinsic pathways. Both pathways are initiated by activation of caspases, and then effector caspases (caspase-3, -6, and -7) are activated to act as executioners of apoptosis [45]. It has been observed that icaritin can induce cell apoptosis in the reported hematological cancer cell lines with flow cytometry analysis [40–44]. Meanwhile, characteristic morphologic changes of apoptosis, like the condensation of nuclear and membrane blebbing, were also found as supporting evidence in MM [27]. Consistently, the proapoptotic proteins, Bax and Bad, were found to be enhanced, while antiapoptotic protein Bcl-2 was suppressed by icaritin in several hematological malignancy cells [41, 42, 44].

Previous findings showed that activated caspase-9, caspase-3, subsequent cleaved PARP, and release of cytochrome c from mitochondria serve as reliable markers of the intrinsic apoptosis pathway [46]. Subsequent studies explored whether the apoptosis induced by icaritin in hematological cancer cells was associated with the activation of the intrinsic pathway and verified that several intracellular signaling pathways in proliferation or apoptosis regulation are involved, such as MEK/ERK, JNK/SAPK, and p38/MAPK [47, 48]. Existing evidence suggested that PI3K/AKT, JAK/STAT, and MAPK/ERK signaling pathways were activated in various hematological malignancies and were considered as a critical target for therapy [49–53]. The pivotal signaling pathways were hence determined to clarify the mechanism of icaritin inducing tumor cell apoptosis. Findings demonstrated that icaritin exerted a remarkable inhibitory effect on the activity of proliferative signaling pathway molecules, restricting the progression of hematological cancer cells. In different hematological cancer cell lines, icaritin was found to work on different signaling pathways; the results were summarized in Table 1.

The JAK-STAT signaling pathway transmits extracellular signals to the nucleus, playing a critical role in transducing signal of a wide array of cytokines and growth factors. These cytokines and growth factors are responsible for various cellular functions, including proliferation, growth, hematopoiesis, and immune response [54–56]. Investigations on hematological malignancies revealed that suppression of icaritin on tumor cells was dependent on inhibition of the JAK-STAT pathway in multiple myeloma [41], chronic myeloid leukemia [40], and extranodal NK/T-cell lymphoma [42].

PI3K-AKT is recognized as a major signaling pathway in cancer development. Through phosphorylation, PI3K-AKT is activated, and the downstream effector participates in regulating tumor cell proliferation, growth, survival, and angiogenesis [57, 58]. Studies suggested that icaritin inhibited the activation of PI3K-AKT, which partly contributed to the inhibition of tumor cell growth in AML and CML [40, 43].

Mitogen-activated protein kinase (MAPK) is a superfamily of protein kinase involved in directing cellular responses to diverse stimuli, such as mitogens, osmotic stress, and proinflammatory cytokines. They play the role of mediating cell functions, including proliferation, differentiation, and apoptosis [59]. Three MAPK families have been precisely characterized, namely, ERK (extracellular signal-regulated kinase), JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase), and p38 kinase [60, 61]. Based on the findings, it has proven that icaritin-regulated expression of MAPK takes part in the suppression of cancer cells in AML and CML [40, 43].

Above all, the mechanism of icaritin inducing of apoptosis through multiple and differential signaling pathways in different hematological malignant tumor cell lines is shown in Figure 1.

2.2. Icaritin Arrested Cell Cycle of Hematological Cancer Cells

There are four distinct phases in the cell cycle, namely, G0, G1, S, and G2/M. Cyclins and cyclin-dependent kinases (CDKs) are two crucial groups of molecules in regulating cell cycle progression. In other words, cell proliferation relies intensively on them as they can translate these signals for accurate and active replication and division. Disrupted cell cycle progression might lead to uncontrolled proliferation, accompanied by the occurrence of cancer [62]. Previous investigations proved that icaritin arrested the cell cycle and blocked multiplication of hematological cancer cells. For different cancer cells, icaritin arrested cells at different cell cycle phase. The impact was associated with icaritin acting on the specific cyclins and CDKs. We summarized the results in Table 2.

2.3. Icaritin Induced Lytic Replication of Epstein–Barr Virus in NK/T-Cell Lymphoma Cells

Epstein–Barr virus (EBV) is known for its essential role in extranodal NK/T-cell lymphoma (ENKL) etiology [63, 64]. EBV-encoded latent membrane protein 1 (LMP1) participates in the proliferation of ENKL cells by activating several survival signals including MAPK, NF-κB, JAK/STAT, and AKT [65–67]. In the previous study for ENKL, icaritin showed proproliferative and proapoptotic effects likely mediated by inhibiting STAT3 and AKT pathways through downregulating LMP1 [42].
EBV has two distinct lifestyles in an infected human host, including a lytic form, in which the virus lyses the host cells to produce infectious virions, and a latent form, in which the virus reserve the host cells to persist in a dormant state. EBV in ENKL specimens is in a latent form [68]. Recently, various researches suggested that activating the EBV latent-lytic switch could be exploited for therapy of EBV-associated tumors such as BL, nasopharyngeal carcinoma, and gastric carcinoma [69–71]. The lytic-phase genes mainly include the two EBV immediate early (IE) genes BZLF1 and BRLF1 and the early gene BMRF1 [72–74]. BZLF1 encodes the lytic replication activator protein, Zta, which initiates the cascade of BRLF1 and BMRF1 to launch the lytic replication [75]. The latent-phase gene EBNA1 is expressed at all latent stages of EBV [76]. Current research demonstrated that icaritin upregulated the expression of BZLF1, BRLF1, and BMRF1 while downregulating the expression of EBNA1 [42]. Besides, treatment with icaritin sensitized the EBV-positive ENKL cells to antiviral ganciclovir (GCV), which was transformed into the active cytotoxic form in the lytic phase [42].

2.4. Icaritin Induced Cell Differentiation of Hematological Malignancy Cells. In the survived icaritin treated K562 cells, we found there were morphological changes, such as reduction in cell volume, accompanied with higher hemoglobin level [40]. Flow cytometry analysis showed that the erythrocyte specific antigens, glycophorin A (CD235a) and transferrin receptor (CD71), were increased [77, 78]. All these results made it clear that icaritin can induce K562 to differentiate to the erythroid lineage with substantiated cell toxicity [40].

The p38 has been proved to mediate icaritin induced cardiomyocyte differentiation [79]. In our previous study, icaritin increased p38 phosphorylation and induced K562 cells to differentiate to erythrocyte, while pretreating with inhibitor on phosphorylation of p38 abolished the differentiation induced by icaritin. [40]. Thus, phosphorylated p38 mediates the cell differentiation induced by icaritin in both normal and leukemic cells.

2.5. Icaritin Restricted Hematological Cancer Invasion In Vivo. In the investigation with NOD/SCID mice, icaritin dramatically reduced disseminated infiltrations of K562 cells in spleen, bone marrow, and liver without overt bone marrow suppression or weight loss compared to the imatinib-treated group [40]. Additionally, in the NOD/SCID mice...
Figure 1: Icaritin induced apoptosis through multiple and differential signaling pathways. Icaritin induces apoptosis by inhibiting PI3K-AKT pathway in AML and CML cells; JAK-STAT pathway in MM, CML, and NKTL cells; and MAPK/ERK pathway in AML and CML cells, while activating MAPK/JNK in CML and MM.
Acknowledgments

This work was funded by National Natural Science Foundation of China (no. 81300427).

References

[1] M. P. Crespo-Ortiz and M. Q. Wei, “Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 247597, 2012.

[2] W. K. Lau, B. H. Goh, H. A. Kadir et al., “Potent PPARgamma ligands from swietenia macrophylla are capable of stimulating glucose uptake in muscle cells,” Molecules, vol. 20, no. 12, pp. 22301–22314, 2015.

[3] Z. Wang, X. Zhang, H. Wang, L. Qi, and Y. Lou, “Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway,” Neuroscience, vol. 145, no. 3, pp. 911–922, 2007.

[4] D. Y. Zhu and Y. J. Lou, “Inducible effects of icariin, icaritin, and desmethylicaritin on directional differentiation of embryonic stem cells into cardiomyocytes in vitro,” Acta Pharmacologica Sinica, vol. 26, no. 4, pp. 477–485, 2005.

[5] J. Huang, L. Yuan, X. Wang, T.-L. Zhang, and K. Wang, “Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro,” Life Sciences, vol. 81, no. 10, pp. 832–840, 2007.

[6] R. Lim, L. Li, N. Chew, and E. Yong, “The prenylflavonoid icaritin enhances osteoblast proliferation and function by signal transducer and activator of transcription factor 3 (STAT-3) regulation of C-X-C chemokine receptor type 4 (CXCR4) expression,” Bone, vol. 105, pp. 122–133, 2017.

[7] X. Ma, C. Ma, W. Shi et al., “Primary cilium is required for the stimulating effect of icaritin on osteogenic differentiation and mineralization of osteoblasts in vitro,” Journal of Endocrinological Investigation, vol. 40, no. 4, pp. 357–366, 2017.

[8] S. Chen, L. Zheng, J. Zhang et al., “A novel bone targeting delivery system carrying phytomolecule icaritin for prevention of steroid-associated osteonecrosis in rats,” Bone, vol. 106, pp. 52–60, 2018.

[9] E. M. Tan, L. Li, I. R. Indran, N. Chew, and E.-L. Yong, “TRAF6 mediates suppression of osteoestrogenesis and prevention of ovariectomy-induced bone loss by a novel prenylflavonoid,” Journal of Bone and Mineral Research, vol. 32, no. 4, pp. 846–860, 2017.

[10] T. Wu, T. Shu, L. Kang et al., “Icaritin, a novel plant-derived osteoinductive agent, enhances the osteogenic differentiation of human bone marrow- and human adipose tissue-derived mesenchymal stem cells,” International Journal of Molecular Medicine, vol. 39, no. 4, pp. 984–992, 2017.

[11] Z. Wu, L. Ou, C. Wang et al., “Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation,” Biomedicine & Pharmacotherapy, vol. 94, pp. 1–9, 2017.

[12] J. Liao, Y. Liu, H. Wu et al., “The role of icaritin in regulating Foxp3/IL17a balance in systemic lupus erythematosus and its effects on the treatment of MRL/lpr mice,” Clinical Immunology, vol. 162, pp. 74–83, 2016.

[13] C. Sun, J. Yang, M. Wang et al., “Icaritin improves antibody-induced thrombocytopenia in a mouse model by regulating t-cell polarization,” Planta Medica, vol. 84, no. 03, pp. 168–175, 2018.

[14] W. P. Tsang, F. Zhang, Q. He et al., “Icaritin enhances mESC self-renewal through upregulating core pluripotency transcription factors mediated by ERalpha,” Scientific Reports, vol. 7, Article ID 40894, 2017.

[15] E. Hwang, P. Lin, H. T. T. Ngo et al., “Icaritin and icaritin recover UVB-induced photoaging by stimulating Nrf2/ARE and reducing AP-1 and NF-kB signaling pathways: a comparative study on UVB-irradiated human keratinocytes,” Photochemical & Photobiological Sciences, vol. 17, no. 10, pp. 1396–1408, 2018.

[16] C. Sun, J. Yang, L. Pan et al., “Improvement of icaritin on hematopoietic function in cyclophosphamide-induced myelosuppression mice,” Immunopharmacology and Immunotoxicology, vol. 40, no. 1, pp. 25–34, 2018.

[17] Z. Li, X. Meng, and L. Jin, “Icaritin induces apoptotic and autophagic cell death in human glioblastoma cells,” American Journal of Translational Research, vol. 8, no. 11, pp. 4628–4643, 2016.

[18] Y. Guo, X. Zhang, J. Meng, and Z. Wang, “An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells,” European Journal of Pharmacology, vol. 658, no. 2-3, pp. 114–122, 2011.

[19] P. B. Gupta, T. T. Onder, G. Jian et al., “Identification of selective inhibitors of cancer stem cells by high-throughput screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009.

[20] H. Han, B. Xu, P. Hou et al., “Icaritin sensitizes human glioblastoma cells to TRAIL-induced apoptosis,” Cell Biochemistry and Biophysics, vol. 72, no. 2, pp. 533–542, 2015.

[21] H. Ma, J. Wang, Y. Chen et al., “Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway,” International Journal of Molecular Medicine, vol. 33, no. 6, pp. 1627–1634, 2014.

[22] C. T. Tiong, C. Chen, S. J. Zhang et al., “A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERalpha protein,” Carcinogenesis, vol. 33, no. 5, pp. 1089–1097, 2012.

[23] X. Wang, N. Zheng, J. Dong et al., “Estrogen receptor-alpha36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 171, pp. 318–327, 2017.

[24] J. Hu, W. Zhu, B. Wei et al., “Antitumoral action of icaritin in LNCaP prostate cancer cells by regulating PEA3/HER2/AR signaling,” Anti-Cancer Drugs, vol. 27, no. 10, pp. 944–952, 2016.

[25] L. Sun, Q. Peng, L. Qu et al., “Anticancer agent icaritin induces apoptosis through caspase-dependent pathways in human hepatocellular carcinoma cells,” Molecular Medicine Reports, vol. 11, no. 4, pp. 3099–3100, 2015.

[26] P. Lu, M. Chen, Y. Liu et al., “Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells,” Oncotarget, vol. 8, no. 14, pp. 22800–22810, 2017.

[27] Q. Zheng, W. Liu, B. Li et al., “Anticancer effect of icaritin on human lung cancer cells through inducing s phase cell cycle arrest and apoptosis,” Journal of Huazhong University of Science and Technology (Medical Sciences), vol. 34, no. 4, pp. 497–503, 2014.

[28] J.-G. Yang, R. Lu, X.-J. Ye, J. Zhang, Y.-Q. Tan, and G. Zhou, “Icaritin reduces oral squamous cell carcinoma progression..."
via the inhibition of STAT3 signaling,” International Journal of Molecular Sciences, vol. 18, no. 1, 2017.
[29] L. Jin, J. Miao, Y. Liu et al., “Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells,” Biomedicine & Pharmacotherapy, vol. 85, pp. 287–295, 2017.
[30] A. Le, Z. Wang, X. Dai et al., “Icaritin inhibits decidualization of endometrial stromal cells,” Experimental and Therapeutic Medicine, 2017.
[31] J. Tong, Q. Zhang, X. Huang et al., “Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells,” Plos One, vol. 6, no. 3, p. e16781, 2011.
[32] S. Han, Y. Gou, D. Jin, J. Ma, M. Chen, and X. Dong, “Effects of Icaritin on the physiological activities of esophageal cancer stem cells,” Biochemical and Biophysical Research Communications, vol. 504, no. 4, pp. 792–796, 2018.
[33] C. Zhou, J. Gu, G. Zhang et al., “AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity,” Oncotarget, vol. 8, no. 9, 2017.
[34] X. Wang, Y. Liu, X. Liu et al., “miR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma,” Oncology Reports, vol. 35, no. 5, pp. 3115–3121, 2016.
[35] Y. Liu, L. Shi, Y. Liu et al., “Activation of PPARY mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme,” Biomedicine & Pharmacotherapy, vol. 100, pp. 358–366, 2018.
[36] H. Li, Q. Liang, and L. Wang, “Icaritin inhibits glioblastoma cell viability and glycosylation by blocking the IL-6/Stat3 pathway,” Journal of Cellular Biochemistry, vol. 120, no. 5, pp. 7257–7264, 2019.
[37] L. Gao, M. Chen, Y. Ouyang et al., “Icaritin induces ovarian cancer cell apoptosis through activation of p38 and inhibition of Akt/mTOR pathway,” Life Sciences, vol. 202, pp. 188–194, 2018.
[38] Z. Wang, R. Wang, Y. Xia et al., “Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells,” Chinese Journal of Natural Medicines, vol. 16, no. 1, pp. 20–28, 2018.
[39] B. Xu, C. Jiang, H. Han et al., “Icaritin inhibits the invasion and epithelial–mesenchymal transition of glioblastoma cells by targeting ENMMPRIN via PTK/ERK/Akt/PI3K activation,” Clinical and Experimental Pharmacology and Physiology, vol. 42, no. 12, pp. 1296–1307, 2015.
[40] J. Zhu, Z. Li, G. Zhang et al., “Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signaling,” Plos One, vol. 6, no. 8, Article ID e23720, 2011.
[41] S. Zhu, Z. Wang, Z. Li et al., “Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3/AKT,” Oncotarget, vol. 6, no. 12, 2015.
[42] T. Wu, S. Wang, J. Wu et al., “Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma,” Journal of Experimental and Clinical Cancer Research, vol. 34, p. 17, 2015.
[43] Q. Li, L. Huai, C. Zhang et al., “Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways,” International Journal of Hematology, vol. 97, no. 5, pp. 617–623, 2013.
[44] Z. J. Li, C. Yao, S. F. Liu et al., “Cytotoxic effect of icaritin and its mechanisms in inducing apoptosis in human Burkitt lymphoma cell line,” BioMed Research International, vol. 2014, Article ID 391512, 2014.
[45] M. Mongiat, G. Ligresti, S. Marastoni, E. Lorenzon, R. Doliama, and A. Colombatti, “Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2,” Molecular and Cellular Biology, vol. 27, no. 20, pp. 7176–7187, 2007.
[46] M. Kurokawa and S. Kornbluth, “Caspases and kinases in a death grip,” Cell, vol. 138, no. 5, pp. 838–854, 2009.
[47] G. S. Burgess, E. A. Williamson, L. D. Cripe et al., “Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase,” Blood, vol. 92, no. 7, pp. 2450–2460, 1998.
[48] C. Yu, G. Krystal, L. Varticovksi et al., “Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Ab1-expressing human leukemia cells,” Cancer Research, vol. 62, no. 1, pp. 188–199, 2002.
[49] Y. Huang, A. de Reyniès, L. de Leval et al., “Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type,” Blood, vol. 115, no. 6, pp. 1226–1237, 2010.
[50] K. Kawachi, T. Ogasawara, M. Yasuyama, and S. Ohkawa, “Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells,” Blood Cells, Molecules, and Diseases, vol. 31, no. 1, pp. 11–17, 2003.
[51] R. Buettner, L. B. Mora, and R. Jove, “Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention,” Clinical Cancer Research, vol. 8, no. 4, pp. 945–954, 2002.
[52] A. C. Bharti, N. Donato, and B. B. Aggarwal, “Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells,” The Journal of Immunology, vol. 171, no. 7, pp. 3863–3871, 2003.
[53] A. K. Samanta, H. Lin, T. Sun, H. Kantarjian, and R. B. Arlinghaus, “Janus kinase 2: a critical target in chronic myelogenous leukemia,” Cancer Research, vol. 66, no. 13, pp. 6468–6472, 2006.
[54] M. Rybinski and A. Gambin, “Model-based selection of the robust JAK–STAT activation mechanism,” Journal of Theoretical Biology, vol. 309, pp. 34–46, 2012.
[55] J. J. O’Shea, M. Pesu, D. C. Borie, and P. S. Changelian, “A new modality for immunosuppression: targeting the JAK/STAT pathway,” Nature Reviews Drug Discovery, vol. 3, no. 7, pp. 555–564, 2004.
[56] C. Liongue, L. A. O’Sullivan, M. C. Trengove, and A. C. Ward, “Evolution of JAK–STAT pathway components: Mechanisms and role in immune system development,” Plos One, vol. 7, no. 3, Article ID e32777, 2012.
[57] D. King, D. Yeomanson, and H. E. Bryant, “PI3 King the lock: the Akt/mTOR pathway,” Journal of Pediatric Hematology/Oncology, vol. 37, no. 4, pp. 245–251, 2015.
[58] J. Peltier, A. O’Neill, and D. V. Schaffer, “PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation,” Developmental Neurobiology, vol. 67, no. 10, pp. 1348–1361, 2007.
K. Aoki, M. Yamada, K. Kunida, S. Yasuda, and M. Matsuda, “Processive phosphorylation of ERK MAP kinase in malignant cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 31, pp. 12675–12680, 2011.

R. E. Scott, P. N. Ghule, J. L. Stein, and G. S. Stein, “Cell cycle gene expression networks discovered using systems biology: significance in carcinogenesis,” Journal of Cellular Physiology, vol. 230, no. 10, pp. 2533–2542, 2015.

R. Suzuki, K. Takeuchi, K. Ohshima, and S. Nakamura, “Extranodal NK/T-cell lymphoma: Diagnosis and treatment cues,” Hematological Oncology, vol. 26, no. 2, pp. 66–72, 2008.

H. Kimura, K. Miyake, Y. Yamauchi et al., “Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by how cytometric in situ hybridization in EBV-associated lymphoproliferative diseases,” The Journal of Infectious Diseases, vol. 200, no. 7, pp. 1078–1087, 2009.

C. Homig-Holzel, C. Hojer, J. Rastelli et al., “Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis,” Journal of Experimental Medicine, vol. 205, no. 6, pp. 1317–1329, 2008.

I. Guasparri, D. Bubman, and E. Cesarman, “EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression,” Blood, vol. 111, no. 7, pp. 3813–3820, 2008.

K. H. Shair, K. M. Bendt, R. H. Edwards et al., “EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas,” Plos Pathogens, vol. 3, no. 11, p. e166, 2007.

Z. Xu, K. Ivatsuki, N. Oyama et al., “The latency pattern of Epstein–Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas,” British Journal of Cancer, vol. 84, no. 7, pp. 920–925, 2001.

J. Zhao, H. Jin, K. F. Cheung et al., “Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer,” Cancer, vol. 118, no. 4, pp. 924–936, 2012.

K. Hui and A. K. Chiang, “Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death,” International Journal of Cancer, no. 10, pp. 2479–2489, 2010.

C. M. Shirley, J. Chen, M. Shamay et al., “Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma,” Blood, vol. 117, no. 23, pp. 6297–6303, 2011.

G. Miller, A. El-Guindy, J. Countryman, J. Ye, and L. Gradoville, “Lytic cycle switches of oncogenic human gammaherpesviruses,” Advances in Cancer Research, vol. 97, pp. 81–109, 2007.

J. L. Kolman, N. Taylor, L. Gradoville, J. Countryman, and G. Miller, “Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras,” Journal of Virology, vol. 70, no. 3, pp. 1493–1504, 1996.

R. Feederle, M. Kost, M. Baumann et al., “The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators,” EMBO Journal, vol. 19, no. 12, pp. 3080–3089, 2000.

S. C. Kenney and J. E. Mertz, “Regulation of the latent-lytic switch in Epstein-Barr virus,” Seminars in Cancer Biology, vol. 26, pp. 60–68, 2014.

N. Sivachandran, X. Wang, and L. Frappier, “Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection,” Journal of Virology, vol. 86, no. 11, pp. 6146–6158, 2012.

L. C. Andersson, C. G. Gahnberg, L. Teerenhovi, and P. Vuopio, “Glycophorin a as a cell surface marker of early erythroid differentiation in acute leukemia,” International Journal of Cancer, vol. 24, no. 6, pp. 717–720, 1979.

S. Uddin, J. Ah-Kang, J. Ulaszek, D. Mahmud, and A. Wickremasinghe, “Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 1, pp. 147–152, 2004.

L. Ding, X. Liang, Y. Hu, D. Zhu, and Y. Lou, “Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro,” Stem Cells and Development, vol. 17, no. 4, pp. 751–760, 2008.

X. Huang, D. Zhu, and Y. Lou, “A novel anticancer agent, icariitin, induced cell growth inhibition, GI arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells,” European Journal of Pharmacology, vol. 564, no. 1-3, pp. 26–36, 2007.

J. He, Y. Wang, F. Duan, H. Jiang, M. Chen, and S. Tang, “Icariitin induces apoptosis of HepG2 Cells via the JNK1 signaling pathway independent of the estrogen receptor,” Planta Medica, vol. 76, no. 16, pp. 1834–1839, 2010.

S. Li, S. J. Priceman, H. Xin et al., “Icariitin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma,” Plos One, vol. 8, no. 12, Article ID e81657, 2013.

C. Zhou, Z. Chen, X. Lu, H. Wu, Q. Yang, and D. Xu, “Icariitin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells,” Tumor Biology, vol. 37, no. 3, pp. 3135–3144, 2016.